Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections, and associated precancerous lesions in an event-triggered interim analysis of the phase III randomised, double-blind, controlled PApilloma TRIal against Cancer In young Adults (PATRICIA). We now assess the vaccine efficacy in the final event-driven analysis.Methods Women (15-25 years) were vaccinated at months 0, 1, and 6. Analyses were done in the according-to-protocol cohort for efficacy (ATP-E; vaccine, n=8093; control, n=8069), total vaccinated cohort (TVC, included all women receiving at least one vaccine dose, regardless of their baseline HPV status; represents the general population, including those who are sexually active; vaccine, n=9319; control, n=9325), and TVC-naive (no evidence of oncogenic HPV infection at baseline; represents women before sexual debut; vaccine, n=5822; control, n=5819). The primary endpoint was to assess vaccine efficacy against cervical intraepithelial neoplasia 2+ (CIN2+) that was associated with HPV-16 or HPV-18 in women who were seronegative at baseline, and DNA negative at baseline and month 6 for the corresponding type (ATP-E). This trial is registered with ClinicalTrials.gov, number NCT00122681.Findings Mean follow-up was 34.9 months (SD 6.4) after the third dose. Vaccine efficacy against CIN2+ associated with HPV-16/18 was 92.9% (96.1% CI 79.9-98.3) in the primary analysis and 98.1% (88.4-100) in an analysis in which probable causality to HPV type was assigned in lesions infected with multiple oncogenic types (ATP-E cohort). Vaccine efficacy against CIN2+ irrespective of HPV DNA in lesions was 30.4% (16.4-42.1) in the TVC and 70.2% (54.7-80.9) in the TVC-naive. Corresponding values against CIN3+ were 33.4% (9.1-51.5) in the TVC and 87.0% (54.9-97.7) in the TVC-naive. Vaccine efficacy against CIN2+ associated with 12 non-vaccine oncogenic types was 54.0% (34.0-68.4; ATP-E). Individual cross-protection against CIN2+ associated with HPV-31, HPV-33, and HPV-45 was seen in the TVC.Interpretation The HPV-16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.Funding GlaxoSmithKline Biologicals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large international randomised control clinical trials have shown that HPV vaccines are safe and highly effective against vaccine-type persistent infection and cervical precancerous lesions in women (with vaccine efficacy ≥93%).6, 7, 8”
In the citing paper
“In the same way, the monophosphoryl lipid A (MPL) from Salmonella enterica has been currently used as adjuvant in the vaccine formulation used against anti-cervical carcinoma [41].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [41]
Citations
Cites
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Self-citationHarper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Self-citationPrevalence of HPV Infection Among Females in the United States
Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., & Markowitz, L. E. (2007) · JAMA · doi:10.1001/jama.297.8.813 · Cited by 1,579
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
Self-citationKyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., & Paraskevaidis, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68181-6 · Cited by 1,120
Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R., Rush, B. B., Glass, A. G., & Schiffman, M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji187 · Cited by 1,053
Bosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Tortolero-Luna, G., Kjaer, S. K., & Muñoz, N. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.064 · Cited by 842
Self-citationSmith, H. O., Tiffany, M. F., Qualls, C. R., & Key, C. R. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5826 · Cited by 736
Arbyn, M., Kyrgiou, M., Simoens, C., Raifu, A. O., Koliopoulos, G., Martin-Hirsch, P., Prendiville, W., & Paraskevaidis, E. (2008) · BMJ · doi:10.1136/bmj.a1284 · Cited by 694
Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., Schiller, J. T., Gonzalez, P., Dubin, G., Porras, C., et al. (2007) · JAMA · doi:10.1001/jama.298.7.743 · Cited by 666
Self-citation
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
“However, in animal models of vaccination, passive antibody is sufficient for protection (18, 50, 171, 177), and the high level of vaccine efficacy against infection in humans suggests that antibody is the effector mechanism (51, 123).”
BackgroundThe Biology and Life-Cycle of Human Papillomaviruses
Doorbar, J., Quint, W., Banks, L., Bravo, I. G., Stoler, M., Broker, T. R., & Stanley, M. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.083 · Cited by 1,528
HPV Vaccination and the Risk of Invasive Cervical Cancer
Lei, J., Ploner, A., Elfström, K. M., Wang, J., Roth, A., Fang, F., Sundström, K., Dillner, J., & Sparén, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917338 · Cited by 1,487
Metadata
- Authors
- Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., Bosch, F., Jenkins, D., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., & Dubin, G.
- Affiliations
- University of Helsinki (FI)
- Universidade Federal do Rio Grande do Sul (BR)
- Mexican Social Security Institute (MX)
- National Taiwan University (TW)
- Väestöliitto (FI)
- Manchester Academic Health Science Centre (GB)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Chulalongkorn University (TH)
- Philippine General Hospital (PH)
- Royal Women's Hospital (AU)
- Queen Mary University of London (GB)
- University of Alberta (CA)
- Universitätsklinikum Würzburg (DE)
- Universitair Ziekenhuis Leuven (BE)
- University of York (GB)
- GlaxoSmithKline (Belgium) (BE)
- University of Tampere (FI)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Paavonen, J
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 374
- Issue
- 9686
- Pages
- 301-314
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2136236728
- Cited by
- 1,655
- References
- 33
- Citations by year
- 2026: 32 · 2025: 41 · 2024: 34 · 2023: 45 · 2022: 66 · 2021: 55 · 2020: 68 · 2019: 72 · 2018: 57 · 2017: 100 · 2016: 96 · 2015: 132 · 2014: 158 · 2013: 151 · 2012: 185
- FWCI
- 121.52
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-09-25)
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Surgery › Genital Health and Disease
- Keywords
- HPV-16/18 AS04-adjuvanted vaccine, HPV vaccine efficacy, HPV16, HPV 18, high-risk HPV genotypes, cervical precancerous lesions, young women, seronegative women, vaccine safety, HPV prevention
- MeSH terms
- Adolescent, Adult, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Double-Blind Method, Female, Humans, Neoplasm Staging, Precancerous Conditions, Safety, Sexual Behavior, Vaginal Smears, Treatment Outcome, Papillomavirus Infections, Mass Vaccination, Human papillomavirus 18, Human papillomavirus 16, Papillomavirus Vaccines, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. https://app.cochat.ai/papers/10.1016/s0140-6736(09)61248-4
- The paper
- Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., . . . Dubin, G. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet. https://doi.org/10.1016/s0140-6736(09)61248-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.